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Abstract
Severe malaria is a major cause of mortality in children, but comprises only a small proportion of 
Plasmodium falciparum infections in naturally exposed populations. The evaluation of vaccines 
that prevent severe falciparum disease will require clinical trials whose primary efficacy endpoint 
will be severe malaria risk during follow-up. Here, we show that such trials are feasible with fewer 
than 1,000 participants in areas with intense malaria transmission during the age interval when 
severe malaria incidence peaks.
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Introduction
Clinical trials of malaria vaccines have used different endpoints to measure activity or 
efficacy, in part because malaria vaccines might reduce the number of malaria-related deaths 
through a variety of mechanisms. As examples, vaccines that prevent infection by targeting 
pre-erythrocytic parasites [1], or that block transmission to mosquitoes [2] and hence 
subsequent human infections, will ultimately have the effect of reducing burden of 
parasitemia and hence severe disease. Further, recent studies indicate that immunity against 
severe malaria can be acquired rapidly [3, 4] without reducing parasitemia [3], supporting 
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efforts to develop vaccines that prevent severe falciparum syndromes [5] by targeting factors 
involved in disease pathogenesis, such as parasite sequestration or virulence.
Despite these encouraging results, the experience of the multicenter RTS,S trial [6] has left 
the impression that many thousands of children are required to test the efficacy of vaccines 
against severe malaria, creating pessimism that future such trials will be undertaken. Here, 
we estimated the risk of severe malaria during infancy in an intensively followed Tanzanian 
birth cohort [3], and calculated sample sizes for future vaccine trials.
Material and Methods
We analyzed data from Mother-Offspring Malaria Studies (MOMS) Project at Muheza 
Designated District Hospital, Muheza. The study design and population are described in 
detail elsewhere [3]. Briefly, children were enrolled at birth, then seen every 2 weeks during 
infancy and every 4 weeks post-infancy for clinical and blood smear examinations, 
regardless of the presence or absence of fever and other symptoms. Whenever children 
became symptomatic, they were also examined by a study clinician. Study participants who 
developed severe malaria according to WHO criteria [7] were treated with parenteral 
quinine.
Ethics
Protocols for procedures used in this study were approved by the International Clinical 
Studies Review Committee of the Division of Microbiology and Infectious Diseases at the 
US National Institutes of Health. Ethical clearance was obtained from the Institutional 
Review Boards of Seattle BioMed and the National Medical Research Coordinating 
Committee in Tanzania. Written informed consent was obtained from mothers prior to 
enrollment.
Statistical analysis
Only children followed for at least one year (N=688), or for less than a year if they 
developed severe malaria during infancy (N=4), were included in our estimation of severe 
malaria risk in the first year of life. We performed sample size calculations for comparisons 
of severe malaria risk by tests of two proportions (power=80%; two-sided significance 
level=0.05). Data analyses were conducted using Stata 11.1 (StataCorp, Texas, United 
States).
Results
In this longitudinal study with active surveillance for infection and disease, 67/692 (9.7%) 
children experienced at least one severe malaria episode during infancy. A clinical trial of a 
vaccine that prevents severe malaria with 50% efficacy and with 1 year follow-up in a 
population where severe malaria risk is similar to ours would have required ~1,000 infants 
(479 in each study arm). In areas with low severe malaria risk (for example, 1%) during the 
same age period, the sample size required would be much higher (Figure 1). Very few 
infants (6/67, 8.9%) suffered their severe malaria episode during the first 4 months of life, 
suggesting that before this age children enjoy some form of intrinsic or passively transferred 
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immunity, and the optimal age to start an active post-vaccination follow-up is after this 
period.
Discussion
In our study, severe malaria risk during the age interval when its incidence peaks [3] is high: 
1 in 10 study children developed at least one episode of severe malarial illness during 
infancy. The overall severe malaria incidence in our study [3] is similar to [8] or higher than 
[9] rates observed at other east African sites, however those studies used passive case 
detection which will underestimate severe malaria incidence. Our intensive follow-up and 
timely provision of treatment were expected to reduce the incidence of severe malaria and 
yet risk remained high. Taken together, our results indicate that vaccine trials designed to 
measure efficacy against life-threatening malaria are feasible with fewer than 1,000 children 
if performed in areas with intense transmission and during the age range when severe 
malaria peaks, even with frequent follow-up and prompt treatment of clinical cases.
The recent RTS,S Phase 3 trial enrolled 15,460 children and was powered (90%) to detect 
vaccine efficacy of 30% against clinical malaria [10] over a wide range of malaria 
transmission intensities. Severe malaria risk was a secondary efficacy endpoint and, 
although that trial involved more than 10 study centers, three sites (Siaya, Kintampo, and 
Kombewa) comprising roughly one third of the study population contributed more than two 
thirds of all severe malaria events in the first year of the study [11]. A vaccine trial using 
severe malaria risk as primary endpoint in an area where the baseline risk is similar to that 
observed in the RTS,S Phase 3 trial (~2.5%) would be feasible, assuming 80% power, with a 
study population < 2,000 individuals, one year of follow-up and vaccine efficacy of 70% or 
more. This baseline risk is probably much higher in some study sites (Siaya, for example), 
which implies that trials undertaken in these areas would probably need to enroll < 1,000 
individuals to test highly effective vaccines against severe malaria.
In this study, we did not observe cerebral malaria episodes. The incidence of this syndrome 
is inversely related to malaria transmission intensity [12] and in areas with high levels of 
transmission, similar to our study site, this clinical presentation is uncommon. Trials to test 
malaria vaccines that specifically target pathogenic processes related to cerebral malaria 
would need to be undertaken in areas with moderate or low transmission, where this 
syndrome represents a higher proportion of severe malaria events. A similar pattern has been 
observed in areas where falciparum epidemiology is transitioning from high to low 
transmission intensity [13]: while the total number of malaria-related hospitalizations might 
remain stable for several years, an increasing proportion of life-threatening malaria presents 
as cerebral malaria. In low transmission areas, severe malaria incidence peaks at older ages 
and over a wider age range, and thus vaccine trials would need to recruit older children and 
likely require a larger sample size or longer follow-up to measure efficacy against cerebral 
malaria.
Over the last 15 years, malaria burden has decreased in Sub-Saharan Africa [14]. As 
exposure to malaria parasites becomes infrequent, the overall risk of developing severe 
disease might not decrease [13, 15] and interventions that specifically prevent severe malaria 
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will become even more important. Vaccines that prevent severe malaria by blocking parasite 
egress from erythrocytes, by neutralizing parasite virulence factors, or by inhibiting parasite 
sequestration in deep vascular beds might play an important role in reducing malaria-related 
mortality. Our observations suggest that trials designed to test these vaccines are feasible in 
areas with high malaria incidence, although setting-specific factors need to be considered: 
incidence might vary from year to year and sample size calculations should be conservative 
and allow for fluctuations in the risk of severe malaria; as transmission declines, the total 
number of severe malaria events might also decline, remain stable or even increase. 
Therefore, clinical trials should be powered for scenarios where life-threatening malaria 
rates decrease with infection incidence, as often happens when trial activities begin. 
Additionally, sample size calculations would be facilitated by realistic expectations of 
vaccine efficacy, but unfortunately animal models do not exist for that purpose. 
Epidemiological studies that measure variations in risk based on hypothetical mechanisms of 
severe disease immunity, such as antibodies against parasite virulence factors, may be useful 
for estimating efficacy of vaccines that target these mechanisms.
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Sample sizes (per study arm; y-axis) for trials that test efficacy against severe malaria by 
baseline severe malaria risk (x-axis) and vaccine efficacy. Calculations for trials in areas 
with risk similar to Muheza (9.7%) are presented in the inset.
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